Compare FDUS & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDUS | CRMD |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.6M | 561.8M |
| IPO Year | 2011 | 2009 |
| Metric | FDUS | CRMD |
|---|---|---|
| Price | $18.08 | $6.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $21.50 | $15.14 |
| AVG Volume (30 Days) | 268.8K | ★ 1.4M |
| Earning Date | 05-29-2026 | 06-05-2026 |
| Dividend Yield | ★ 11.83% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | ★ 2.08 | 2.04 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $6.01 | $1.10 |
| Revenue Next Year | $4.28 | N/A |
| P/E Ratio | $8.67 | ★ $3.15 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $17.41 | $5.60 |
| 52 Week High | $22.09 | $17.43 |
| Indicator | FDUS | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 34.53 |
| Support Level | N/A | N/A |
| Resistance Level | $20.55 | $7.44 |
| Average True Range (ATR) | 0.54 | 0.27 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.73 | 23.40 |
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.